2024 AUA Recaps : Episode 2

News

Video

AUA 2024: Dr. Zorn recaps key BPH research

Author(s):

Urology Times staff

In this video, Kevin C. Zorn, MD, FRCSC, FACS, discusses key BPH data from the 2024 American Urological Association Annual Meeting.

Current Time 0:00
Duration 25:27
Loaded: 0%
Stream Type LIVE
Remaining Time 25:27
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In this video, Kevin C. Zorn, MD, FRCSC, FACS, recaps data in benign prostatic hyperplasia (BPH) that was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Zorn is the founder and director of BPH Canada in Montreal.

    The following research is discussed:

    1. P2-13: Preliminary RCT Analysis of Minimally Invasive Surgery vs. Medication in the Initial Treatment of BPH-Associated LUTS

    2. MP27-04: Multi-center report on acute clinical outcomes with Rivermark FloStent™

    3. MP20-02: Aquablation at 4-years: the largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

    4. MP46-03: Preservation of Sexual Function with Optilume: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

    5. MP20-05: Day Case Aquablation: First Published Experience Report in Ambulatory Surgical Center (ASC)

    Related Videos
    Karyn S. Eilber, MD, answers a question during a Zoom video interview
    Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
    Woman at doctor | Image Credit: © rocketclips - stock.adobe.com
    Optimizing onabotA for OAB: What are some common misconceptions?
    Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
    Ian Metzler, MD, on the role for telemedicine, digital health tools in stone disease
    Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
    Nitin Yerram, MD, highlights new resource center for patients with renal cell carcinoma
    Perry Xu, MD, answers a question during Zoom video interview
    Perry Xu, MD, discusses PCNL’s role in the age of minimally invasive URS
    Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
    Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
    Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
    Ekene Enemchukwu, MD, on the need for better education on GSM, vaginal estrogen
    Drug costs | Image Credit: © pixelrobot - stock.adobe.com
    Urologist discusses drug cost savings, price transparency
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
    Urinary bladder | Image Credit: © magicmine - stock.adobe.com
    Expert describes implications of neoadjuvant durvalumab approval in MIBC
    Related Content
    Welcome to Fabulous Las Vegas Neon Sign | Image Credit: © somchaij - stock.adobe.com
    April 21st 2025

    AUA 2025: What to watch for in urologic oncology

    Benjamin P. Saylor Hannah Clarke
    We preview several noteworthy P2 presentations in the urologic oncology space.
    Former MLB player Dave Winfield shares lessons from baseball, philanthropy
    November 15th 2024

    Former MLB player Dave Winfield shares lessons from baseball, philanthropy

    Urology Times staff
    In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
    3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
    February 18th 2025

    RETAIN-2 interim data promising for dose-dense MVAC plus nivolumab in MIBC

    Benjamin P. Saylor
    “Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.
    blurred photo of a clinic hallway
    May 28th 2023

    2023 AUA highlights in benign urology

    Urology Times staff
    Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
    Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
    February 17th 2025

    Casdatifan is linked with promising safety, efficacy in clear cell RCC

    Benjamin P. Saylor
    “Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
    Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
    February 16th 2025

    Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

    Benjamin P. Saylor
    "The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
    © 2025 MJH Life Sciences

    All rights reserved.